Open AccessEvaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
Author(s) -
Vincent Chung,
Ferdynand Kos,
Nicola Hardwick,
Yate-Ching Yuan,
Joseph Chao,
D Li,
James Waisman,
Minzhao Li,
Kathryn Zurcher,
Paul Frankel,
Don J. Diamond
Publication year - 2018
Publication title -
clinical and translational oncology
Language(s) - English
Resource type - Journals
eISSN - 1699-3055
pISSN - 1699-048X
DOI - 10.1007/s12094-018-1932-2
Subject(s) - medicine , pembrolizumab , immune system , clinical trial , modified vaccinia ankara , oncology , cancer , immunotherapy , breast cancer , immunology , vaccinia , biochemistry , chemistry , gene , recombinant dna
Vaccination of cancer patients with p53-expressing modified vaccinia Ankara virus (p53MVA) has shown in our previous studies to activate p53-reactive T cells in peripheral blood but without immediate clinical benefit. We hypothesized that the immunological responses to p53MVA vaccine may require additional immune checkpoint blockade to achieve clinically beneficial levels. We therefore conducted a phase I trial evaluating the combination of p53MVA and pembrolizumab (anti-PD-1) in patients with advanced solid tumors.